It is clear that T cells modified to express chimeric 4-1BB signaling molecules can control tumors, arguing for direct effects of 4-1BB on CD8 T cells in cancer therapy (for example, [50]–[52]). This evidence concerns the gene TNFRSF9 and cancer.